Targeted therapy better for repeat kidney cancer patients than FDA-approved counterpart

(City of Hope) Kidney cancer patients who had already tried two or three different treatments had improved chances of preventing cancer progression with an experimental drug called tivozanib compared to an alternative approved by the FDA, reports a City of Hope-led study. Published in The Lancet Oncology, the study is the first to show the benefit of tivozanib for patients with renal cell carcinoma (kidney cancer) who had received two or more previous therapies.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

Conclusion: Our study demonstrated that the aberrant expression of CDCA gene family members plays an indispensable role in tumorigenesis. PMID: 31955607 [PubMed - as supplied by publisher]
Source: Future Medicine: Biomarkers in Medicine - Category: Internal Medicine Tags: Biomark Med Source Type: research
Publication date: Available online 21 January 2020Source: Life SciencesAuthor(s): Afsane Bahrami, Vanessa Bianconi, Matteo Pirro, Hossein M. Orafai, Amirhossein SahebkarAbstractAutophagy is a conserved “self-eating” recycling process which removes aggregated or misfolded proteins, or defective organelles, to maintain cellular hemostasis. In the autophagy-lysosome pathway (ALP), clearance of unwanted debris and materials occurs through the generation of the autophagosome, a complex of double-membrane bounded vesicles that form around cytosolic cargos and catabolize their contents by fusion to lysosomes. In tumor...
Source: Life Sciences - Category: Biology Source Type: research
ConclusionIn this study we screened many false positive target genes predicted for miR-299-5. Finally, 13 essential hub genes were introduced. These genes potentially are potent cancer biomarkers and suitable therapeutic targets in targeted cancer therapies.Graphical abstract
Source: Meta Gene - Category: Genetics & Stem Cells Source Type: research
ConclusionFer1L4 expression significantly correlates with aspects of tumor aggressiveness. Based on this impact on tumor progression and its influence as an independent prognostic factor, Fer1L4 appears to exert properties as an oncogene in ccRCC. As a prognostic tissue biomarker, further functional investigations are warranted to investigate Fer1L4 as a potential therapeutic target.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
Hereditary papillary renal carcinoma (HPRC) is a rare autosomal dominant disease characterized by the development of multiple papillary type I renal cell carcinomas. This hereditary kidney cancer form is caused by activating mutations in MET. Descriptions of patients with HPRC are scarce in the world literature, and no cases have been described in open sources in Russia. Here, we describe a 28-year-old female Russian patient with 7 and 10 primary papillary renal cell carcinomas in the left and right kidneys, respectively. The patient did not have a family history of any of the known hereditary cancer syndromes. A comprehen...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Authors: Feng X, Zhang M, Meng J, Wang Y, Liu Y, Liang C, Fan S Abstract We aimed to investigate the potential mechanisms of progression and identify novelprognosis-related biomarkers for papillary renal cell carcinoma (PRCC) patients. The relateddata were derived from The Cancer Genome Atlas (TCGA), and then, analyzed by Weightedgene co-expression network analysis (WGCNA). The correlation between each module andthe clinical traits were analyzed by Pearson's correlation analysis. Pathway analysis wasconducted to reveal potential mechanisms. Hub genes within each module were screenedby intra-module analysis, and vis...
Source: Oncology Research - Category: Cancer & Oncology Tags: Oncol Res Source Type: research
Conclusion: Advanced RCC has high morbidity and mortality with an increasing prevalence. Following tyrosine kinase inhibitors, checkpoint inhibitors have a great influence on treatment of advanced RCC, especially the combination of these two strategies. In 2019 these combined strategies demonstrated 5% complete remission with up to 60% objective response rate. While not immediately, but perhaps in the near future, advanced RCC will become a manageable chronic disease, even if a cure is not possible. PMID: 31942809 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
Grasso Fulvio Magni Protein N-glycosylation is one of the most important post-translational modifications and is involved in many biological processes, with aberrant changes in protein N-glycosylation patterns being closely associated with several diseases, including the progression and spreading of tumours. In light of this, identifying these aberrant protein glycoforms in tumours could be useful for understanding the molecular mechanism of this multifactorial disease, developing specific biomarkers and finding novel therapeutic targets. We investigated the urinary N-glycoproteome of clear cell renal cell carcinoma ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
e;n D, Bajory Z, Kulka J, Iványi B Abstract Xp11.2 translocation carcinoma is a distinct subtype of renal cell carcinoma characterized by translocations involving the TFE3 gene. Our study included the morphological, immunohistochemical and clinicopathological examination of 28 Xp11.2 RCCs. The immunophenotype has been assessed by using CA9, CK7, CD10, AMACR, MelanA, HMB45, Cathepsin K and TFE3 immunostainings. The diagnosis was confirmed by TFE3 break-apart FISH in 25 cases. The ages of 13 male and 15 female patients, without underlying renal disease or having undergone chemotherapy ranged from 8 to 72. The...
Source: Pathology Oncology Research - Category: Pathology Authors: Tags: Pathol Oncol Res Source Type: research
es Claude Cochet Odile Filhol Clear cell renal cell carcinoma (ccRCC) is the third type of urologic cancer. At time of diagnosis, 30% of cases are metastatic with no effect of chemotherapy or radiotherapy. Current targeted therapies lead to a high rate of relapse and resistance after a short-term response. Thus, a major hurdle in the development and use of new treatments for ccRCC is the lack of good pre-clinical models that can accurately predict the efficacy of new drugs and allow the stratification of patients into the correct treatment regime. Here, we describe different 3D cultures models of ccRCC, emphasizing...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Kidney Cancer | Renal Cell Carcinoma | Study | Urology & Nephrology